Gennex Laboratories reported a 31% year-on-year increase in standalone revenue from operations to ₹36.67 crore for the quarter ended June 30, 2026. This marks a significant acceleration from the ₹27.90 crore logged in Q1FY26. However, profitability contracted slightly, with net profit after tax falling 4% to ₹3.96 crore compared to ₹4.15 crore in the prior year period.

The Board of Directors approved the unaudited standalone and consolidated financial results during its meeting held on August 14, 2026. The results were subsequently published in Business Standard and Saksham on August 15, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Standalone revenue from operations rose to ₹36.67 crore from ₹27.90 crore in Q1FY26. In the preceding quarter (Q4FY26), revenue stood at ₹38.01 crore, indicating a sequential dip of approximately 4%. Consolidated revenue from operations increased 15% year-on-year to ₹41.85 crore, up from ₹36.45 crore in Q1FY26.

Net profit before tax on a standalone basis declined 13% to ₹4.21 crore from ₹4.85 crore in the same quarter last year. After-tax net profit fell 4% to ₹3.96 crore. On a consolidated basis, net profit after tax dropped 7% to ₹4.67 crore from ₹5.02 crore in Q1FY26.

Earnings per share (basic) on a standalone basis were ₹0.163, down from ₹0.179 in Q1FY26. Consolidated basic EPS was ₹0.192, compared to ₹0.217 in the previous year.

What the Numbers Show

The divergence between revenue growth and profit contraction highlights margin pressure during the quarter. While standalone revenue surged 31%, net profit before tax fell 13%. This suggests that costs or expenses grew at a faster rate than top-line sales, compressing operational efficiency relative to the prior year period. The sequential decline in revenue from ₹38.01 crore in Q4FY26 to ₹36.67 crore in Q1FY27 further indicates potential seasonality or normalization in demand post-fiscal year end.

Gennex Laboratories has closed its trading window for dealing in the company's securities effective July 01, 2026. This measure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders. The restriction is intended to prevent insider trading while the company prepares to release its financial performance data for the recent quarter.

The trading window will remain shut until 48 hours after the public announcement of the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The closure period is standard practice to ensure that sensitive information is not misused ahead of formal disclosures. The specific date for the Board of Directors meeting to approve these results has not yet been finalized and will be informed in due course.

Consequently, all promoters, designated persons, and connected persons have been advised not to trade in the securities of Gennex Laboratories Limited either directly or indirectly during this period. The company has communicated this regulatory compliance to the BSE Limited, The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited to ensure the information is placed on record.

Key Compliance Details